Amyloidosis inhibition, a new frontier of the protein corona

Pengyu Chen, Feng Ding, Rong Cai, Ibrahim Javed, Wen Yang, Zhenzhen Zhang, Yuhuan Li, Thomas P. Davis, Pu Chun Ke, Chunying Chen

Research output: Contribution to journalReview ArticleResearchpeer-review

30 Citations (Scopus)


The protein corona has served as a central dogma and a nuisance to the applications of nanomedicine and nanobiotechnology for well over a decade. Here we introduce the emerging field of amyloidosis inhibition, which aims to understand and harness the interfacial phenomena associated with a nanoparticle interacting with pathogenic amyloid proteins. Much of this interaction correlates with our understanding of the protein corona, and yet much differs, as elaborated for the first time in this Perspective. Specifically, we examine the in vitro, in silico and in vivo features of the new class of “amyloid protein corona”, and discuss how the interactions with nanoparticles may halt the self-assembly of amyloid proteins. As amyloidosis is driven off pathway by the nanoparticles, the oligomeric and protofibrillar populations are suppressed to ameliorate their cytotoxicity. Furthermore, as amyloid proteins spread via the transport of bodily fluids or cross seeding, amyloidosis is inherently associated with dynamic proteins and ligands to evoke the immune system. Accordingly, we ponder the structural and medical implications of the amyloid protein corona in the presence of their stimulated cytokines. Understanding and exploiting the amyloid protein corona may facilitate the development of new theranostics against a range of debilitating amyloid diseases.

Original languageEnglish
Article number100937
Number of pages13
JournalNano Today
Publication statusPublished - Dec 2020


  • Amyloid protein corona
  • Amyloidosis
  • Cytokine
  • Nanoparticle inhibitor
  • Protein corona

Cite this